DGAP-Adhoc: Nagarro SE: Further increase in revenue guidance for FY 2022
2022. július 21., csütörtök, 18:06
DGAP-Ad-hoc: Nagarro SE / Key word(s): Forecast July 21, 2022 – The Nagarro SE Management Board today analyzed the year-to-date developments and outlook for the rest of the year and consequently decided to revise the company"s guidance for 2022. The company revised its estimate for 2022 revenue upwards from €770 million to €800 million. The estimate for gross margin was revised from 28% to 27%, while the estimate for Adjusted EBITDA margin remained at 14%. Note: This document contains supplementary non-IFRS financial measures. Gross margin and Adjusted EBITDA margin are alternative performance measures that are not defined in accordance with international accounting standards. Nagarro uses these measures to enable better comparability of the business over time and within the industry. For details on alternative performance measures see Nagarro SE Annual Report 2021. This document also includes forward-looking statements that represent management"s expectations based on assumptions and estimates, but future actual developments and future actual results may deviate from these assumptions and estimates.
Nagarro SE Nagarro SE (ISIN: DE000A3H2200 | WKN: A3H220 | FRA: NA9)
|
Language: | English |
Company: | Nagarro SE |
Einsteinstraße 172 | |
81677 München | |
Germany | |
Phone: | 089 9984210 |
Internet: | www.nagarro.com |
ISIN: | DE000A3H2200 |
WKN: | A3H220 |
Indices: | SDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1403429 |
End of Announcement | DGAP News Service |
1403429 21-Jul-2022 CET/CEST
Közzétételek - archívum
-
» PJSC Magnitogorsk Iron and Steel Works: MMK notifies on additional extension of consent solicitation process
[2022.06.30. 13:00]
-
» Evonik Industries and Laxxon Medical see future in 3D screen printed pharmaceuticals
[2022.03.08. 15:02]
-
» Evonik und Laxxon Medical sehen Zukunftsmarkt für 3D-Druck von Tabletten
[2022.03.08. 15:02]
-
» "Game Changing" Technology Enables QR Code Integration with 3D Screen Printing
[2022.02.16. 17:31]
-
» Laxxon Medical to Participate in the 24th Annual Needham Virtual Growth Conference
[2022.01.07. 16:40]
-
» EQS-News: Focus Financial Partners Announces the Launch of Beryllus Capital in a Leading-Edge Joint Venture with the Hinduja Group
[2021.03.22. 12:45]
-
» DGAP-Adhoc: TRATON SE: TRATON und Navistar einig über Fortsetzung der Gespräche
[2020.10.16. 18:43]
-
» DGAP-Adhoc: TRATON SE: TRATON and Navistar agreement in principle
[2020.10.16. 18:43]
-
» EQS-News: International Cannabis Company Kaya Holdings, Inc. Enters into Strategic Partnership with U.S.-Israeli Cannabis Innovation Lab
[2020.07.22. 15:00]
-
» EQS-News: International Cannabis Company Kaya Holdings, Inc. and Greek Joint Venture Partner to Launch "Cannamo(TM)" Brand of CBD Pet Products
[2020.07.08. 17:15]